Canadian biotech to discontinue omega-3 program after second PhIII fails on significant triglyceride reduction
It’s been an eventful 12 months or so for the omega-3 market, but one company’s latest attempt to use the approach for severe hypertriglyceridemia came …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
